Hepatitis B Virus
Researchers from South Korea, Taiwan and Italy report recent findings in hepatitis B virus
Published in Hepatitis Weekly, October 9th, 2006
Study 1: A study from South Korea has reported on the increased risk of adefovir resistance in patients with lamivudine (LAM)-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil (ADV) monotherapy.
"Although ADV has a unique profile of delayed and infrequent resistance in treatment-naive chronic hepatitis B patients, the association of ADV resistance with previous LAM resistance is not well understood.
"We compared the emergence of the ADV-resistant mutations rtA181V/T and rtN236T between LAM-resistant patients and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2006-10-09)
More Articles from Hepatitis Weekly
- Apoptosis
Hepatoma cell apoptosis inhibited by hepatitis C virus non-structural protein - Hepatitis B Virus
Hepatitis B virus putative intergenotype recombinants identified - Hepatitis C Virus
Hepatitis C polymerase inhibitor binding reveals a new inhibition mechanism - Hepatitis C Virus
Hepatitis C virus core protein induces interleukin production in lymphoma - Hepatitis C Virus
Hepatitis C virus interacts with a human platelet glycoprotein - Blood Safety
U.S. FDA fines American Red Cross $4.2 million for failure to meet established blood safety laws - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
